Acutaas Chemicals Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the Q2 FY24 earnings call transcript. - The company has ongoing CAPEX plans, including a 16-megawatt solar power plant project with a CAPEX of around Rs. 65-70 crores and Ankleshwar facility expansion, with Rs. 100-110 crores expected by year-end. - No specific discussions or announcements about raising funds via debt or equity were made during the call. - Management focused on operational updates, acquisitions (Baba Fine Chem), pricing pressures, and growth prospects without addressing new capital raising. - For any missed or follow-up queries, management suggested contacting their IR advisor (E&Y), indicating no immediate public fundraising announcements. Hence, based on the available transcript till November 9, 2023, there is no current or near-future fundraising indicated.

- Ami Organics has approved a 16-megawatt captive solar power plant project with a CAPEX of approximately Rs. 65-70 crores; installation is expected to complete by the end of the financial year. - Additionally, a 5-megawatt solar power plant is already in progress, which will help offset electricity expenses once operational. - CAPEX for H1 FY24 was Rs. 105 crores, with another Rs. 100-110 crores expected by year-end. - The Ankleshwar facility, acquired from Gujarat Organics with an investment of around Rs. 190 crores, will be operational by mid-December 2023, ramping up in Q4 FY24 to contribute to revenues. - The Ankleshwar site's capacity includes 33% allocated to the Fermion contract (fully booked) with 66% capacity free for future demand till FY27. - Ongoing focus on expanding strategic partnerships and commercial supplies—e.g., the Fermion contract with plans to start supplying two more intermediates commercially in H2 FY25.

- FY24 revenue growth target revised downward to 18%-22% from earlier 22%-25%, mainly due to pricing erosion despite volume growth of 20%-25%. - Volume growth expected to remain strong; value/realization affected by pricing pressures. - Muted performance expected in FY24 due to delayed product launches and acquisition/integration of Baba Fine Chemicals; FY25 anticipated to be better than both FY23 and FY24. - Baba Fine Chemicals integration year in FY24; exponential growth targeted in coming years with aim for Rs. 200-250 crore topline in 4-5 years. - Full utilization of Ankleshwar facility capacity targeted by FY27 with ongoing pipeline discussions. - Specialty chemicals segment targeting to achieve 2.5x growth over next couple of years. - New product launches (e.g., UV absorber, electrolyte additives) expected to contribute revenue from Q3 FY24 onwards. - Fermion contract revenues expected to ramp up fully by H2 FY25.

- FY24 is expected to be a muted year in terms of growth, with some deferred revenue impacting quarterly performance. - FY25 is projected to be better than both FY23 and FY24, with significant ramp-up in operations, especially from new contracts and Ankleshwar facility. - Company targets operating the Ankleshwar facility at full capacity by FY27. - Volume growth is expected to continue strongly at 20%-25%, though price erosion has moderated top-line growth guidance from 22-25% to 18-22% for FY24. - EBITDA margin guidance is around 6%-7% improvement on a broader level; margin recovery expected starting Q3 FY24 as raw material prices stabilize. - Baba Fine Chem subsidiary expected to scale up post consolidation in FY24, targeting Rs. 200-250 crore revenue in 4-5 years. - New product launches and contract ramp-ups (e.g., Fermion) will contribute to improved profitability from FY25 onward.

- Ami Organics has a strong order book for H2 FY24, signaling expected robust performance in the coming quarters (Page 6). - The company has ongoing contracts including a Fermion contract with supply of 3 intermediates; one intermediate supply has started, and validations for the remaining two intermediates will begin in the 2nd half of December, targeting commercial supply in H2 FY25 (Page 13). - Ankleshwar facility has 33% capacity allocated to Fermion, which is fully booked, with remaining capacity available to fulfill future demand until FY27 (Page 12). - The company is reducing inventory for domestic requirements post pricing pressure and expects recovery in positioning and margins from here onwards (Page 6). - New validations and product launches are anticipated, supporting the order pipeline and revenue visibility.